MY153057A - Tryclic compounds,compositions and methods - Google Patents

Tryclic compounds,compositions and methods

Info

Publication number: MY153057A
Authority: MY; Malaysia
Prior art keywords: compounds; tryclic; compositions; methods; glucocorticoid receptor
Prior art date: 2007-02-02

Application number

Other languages

English (en)

Inventor

Devraj Rajesh Venkateswaran

Crescenzo Gary A De

Hu Xiao

Jerome Kevin Dewayne

Obukowicz Mark Gerard

Olson Lisa

Rucker Paul Vincent

Webber Ronald Keith

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-02

Filing date

2008-01-25

Publication date

2014-12-31

2008-01-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2014-12-31 Publication of MY153057A publication Critical patent/MY153057A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings

MYPI20123293 2007-02-02 2008-01-25 Tryclic compounds,compositions and methods MY153057A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88798107P	2007-02-02	2007-02-02

Publications (1)

Publication Number	Publication Date
MY153057A true MY153057A (en)	2014-12-31

Family

ID=39315208

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
MYPI20123293 MY153057A (en)	2007-02-02	2008-01-25	Tryclic compounds,compositions and methods
MYPI20093089A MY146087A (en)	2007-02-02	2008-01-25	Tricyclic compound, compositions, and methods
MYPI20093135A MY148780A (en)	2007-02-02	2008-01-28	Tricyclic compounds, compositions, and methods

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
MYPI20093089A MY146087A (en)	2007-02-02	2008-01-25	Tricyclic compound, compositions, and methods
MYPI20093135A MY148780A (en)	2007-02-02	2008-01-28	Tricyclic compounds, compositions, and methods

Country Status (43)

Country	Link
US (7)	US7547714B2 (es)
EP (1)	EP2114970B1 (es)
JP (1)	JP4599462B2 (es)
KR (2)	KR101107949B1 (es)
CN (2)	CN101616925B (es)
AP (1)	AP2455A (es)
AR (2)	AR065135A1 (es)
AT (1)	ATE518872T1 (es)
AU (1)	AU2008211613B2 (es)
BR (1)	BRPI0808634A2 (es)
CA (1)	CA2676670C (es)
CL (2)	CL2008000330A1 (es)
CO (2)	CO6190603A2 (es)
CR (2)	CR10948A (es)
CU (2)	CU23824A3 (es)
CY (2)	CY1110962T1 (es)
DK (1)	DK2114970T3 (es)
DO (1)	DOP2009000190A (es)
EA (1)	EA016494B1 (es)
EC (2)	ECSP099552A (es)
ES (2)	ES2368286T3 (es)
GE (2)	GEP20125404B (es)
GT (2)	GT200900209A (es)
HK (1)	HK1135108A1 (es)
HN (2)	HN2008000179A (es)
HR (1)	HRP20110702T1 (es)
IL (1)	IL199972A (es)
MA (2)	MA31158B1 (es)
MX (1)	MX2009008284A (es)
MY (3)	MY153057A (es)
NI (2)	NI200900149A (es)
NZ (1)	NZ578638A (es)
PE (2)	PE20081736A1 (es)
PL (1)	PL2114970T3 (es)
PT (2)	PT2114970E (es)
RS (2)	RS51970B (es)
SI (1)	SI2114970T1 (es)
SV (2)	SV2009003346A (es)
TN (1)	TN2009000324A1 (es)
TW (2)	TWI373466B (es)
UA (2)	UA94639C2 (es)
WO (1)	WO2008093227A1 (es)
ZA (2)	ZA200906060B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1094757C (zh)	1996-07-24	2002-11-27	沃尼尔·朗伯公司	用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
CN101616925B (zh)	2007-02-02	2012-05-23	辉瑞产品公司	三环化合物及其作为糖皮质激素受体调节剂的用途
PT2307375E (pt) *	2008-07-28	2015-01-14	Pfizer	Compostos da fenantrenona, composições e métodos
WO2010059894A1 (en) *	2008-11-21	2010-05-27	Bridge Pharma, Inc.	Ocular formulations of norketotifen
US20100136096A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100136094A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100136095A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100136097A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100135983A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Anti-inflammatory compositions and methods
US20100137844A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Delivery devices for modulating inflammation
US20100137246A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Anti-inflammatory compositions and methods
CA2798697A1 (en)	2010-05-10	2011-11-17	Radikal Therapeutics Inc.	Lipoic acid and nitroxide derivatives and uses thereof
SG187909A1 (en) *	2010-08-27	2013-03-28	Corcept Therapeutics Inc	Pyridyl-amine fused azadecalin modulators
MX2013010576A (es) *	2011-03-15	2014-03-12	Abbvie Inc	Moduladores de receptores de hormonas nucleares.
US8545904B1 (en)	2012-06-05	2013-10-01	Liquid Innovators, LLC	Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) *	2012-07-05	2016-01-05	Abbvie Inc.	Process for preparing bicyclic amine derivatives
TW201422590A (zh)	2012-09-07	2014-06-16	Abbvie Inc	雜環核激素受體調節劑
WO2014094357A1 (en)	2012-12-21	2014-06-26	Abbvie Inc.	Heterocyclic nuclear hormone receptor modulators
DE202015104742U1 (de)	2014-05-16	2015-10-08	Liqwd, Inc.	Keratinbehandlungsformulierungen und Verwendungen derselben
JP6873906B2 (ja)	2014-10-20	2021-05-19	オイスターポイントファーマインコーポレイテッド	眼の病状の治療方法
CN104591988A (zh) *	2014-12-29	2015-05-06	甘肃省化工研究院	6-溴-2-萘满酮的合成方法
CN113350353A (zh)	2015-03-23	2021-09-07	墨尔本大学	呼吸性疾病的治疗
EP3970724A1 (en)	2016-04-07	2022-03-23	Oyster Point Pharma, Inc.	Methods of treating ocular conditions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2576025B1 (fr)	1985-01-14	1987-01-23	Roussel Uclaf	Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) *	1986-06-19	1988-08-26	Pechiney Aluminium	Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
IL122740A (en)	1997-01-15	2003-09-17	Akzo Nobel Nv	16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
WO2000066522A1 (en) *	1999-04-30	2000-11-09	Pfizer Products Inc.	Glucocorticoid receptor modulators
WO2001005229A1 (en)	1999-07-15	2001-01-25	The General Hospital Corporation	Non-defective epstein-barr viral vector
IL180679A0 (en) *	2000-10-27	2009-02-11	Pfizer Prod Inc	Process for the preparation of non-steroidal glucocorticoid receptor modulators
ATE327974T1 (de)	2000-10-28	2006-06-15	Pfizer Prod Inc	Modulatoren des glucocorticoid-rezeptors
EP1201660B1 (en)	2000-10-30	2005-08-31	Pfizer Products Inc.	Glucocorticoid receptor modulators
US6462661B2 (en) *	2000-11-20	2002-10-08	Seagate Technology Llc	RF ID tag attachment to a disc drive
MXPA03011935A (es)	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
CN1556708A (zh)	2001-08-31	2004-12-22	�Ƹ��	抑制成年唐氏综合症患者认知退化的方法
CA2460144C (en)	2001-09-27	2010-11-02	Universite De Liege	Pyridinic sulfonamide derivatives, method of production and use thereof
DE10164366C1 (de) *	2001-12-28	2003-06-05	Rehau Ag & Co	Permanentkathode
ES2305434T3 (es)	2002-02-01	2008-11-01	Pfizer Products Inc.	Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
US8476254B2 (en)	2002-07-02	2013-07-02	Corcept Therapeutics, Inc.	Methods for treating psychosis associated with interferson-α therapy
PT1521733E (pt)	2002-07-08	2014-10-29	Pfizer Prod Inc	Moduladores do recetor de glucocorticoides
US8450379B2 (en)	2002-11-05	2013-05-28	Corcept Therapeutics, Inc.	Methods for treating migraine
JP2006516651A (ja)	2003-02-04	2006-07-06	コーセプトセラピューティクス，インコーポレイテッド	産後精神病の処置のための抗糖質コルチコイド
US8097606B2 (en)	2003-07-23	2012-01-17	Corcept Therapeutics, Inc.	Antiglucocorticoids for the treatment of catatonia
US20050080061A1 (en)	2003-07-23	2005-04-14	Corcept Therapeutics, Inc.	Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
TW200512181A (en)	2003-09-26	2005-04-01	Tanabe Seiyaku Co	Amide-type carboxamide derivatives
ES2398239T3 (es) *	2003-11-10	2013-03-14	The Scripps Research Institute	Composiciones y procedimientos para inducir la desdiferenciación celular
CA2545020A1 (en) *	2003-11-13	2005-05-26	Pfizer Products Inc.	Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en)	2005-02-14	2012-08-11	Msd Oss Bv	Non steroidal glucocorticoid receptor modulators
JP2009535430A (ja)	2006-05-02	2009-10-01	コーセプトセラピューティクス，インコーポレイテッド	Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
MX2009008286A (es) *	2007-02-02	2009-08-12	Pfizer Prod Inc	Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
CN101616925B (zh) *	2007-02-02	2012-05-23	辉瑞产品公司	三环化合物及其作为糖皮质激素受体调节剂的用途

2008
- 2008-01-25 CN CN2008800052954A patent/CN101616925B/zh not_active Expired - Fee Related
- 2008-01-25 SI SI200830393T patent/SI2114970T1/sl unknown
- 2008-01-25 MX MX2009008284A patent/MX2009008284A/es active IP Right Grant
- 2008-01-25 MY MYPI20123293 patent/MY153057A/en unknown
- 2008-01-25 PT PT08702351T patent/PT2114970E/pt unknown
- 2008-01-25 ES ES08702351T patent/ES2368286T3/es active Active
- 2008-01-25 AU AU2008211613A patent/AU2008211613B2/en not_active Ceased
- 2008-01-25 AP AP2009004942A patent/AP2455A/xx active
- 2008-01-25 MY MYPI20093089A patent/MY146087A/en unknown
- 2008-01-25 RS RS20110429A patent/RS51970B/en unknown
- 2008-01-25 PL PL08702351T patent/PL2114970T3/pl unknown
- 2008-01-25 JP JP2009547778A patent/JP4599462B2/ja not_active Expired - Fee Related
- 2008-01-25 EA EA200970666A patent/EA016494B1/ru not_active IP Right Cessation
- 2008-01-25 UA UAA200907728A patent/UA94639C2/ru unknown
- 2008-01-25 AT AT08702351T patent/ATE518872T1/de active
- 2008-01-25 KR KR1020097018289A patent/KR101107949B1/ko not_active IP Right Cessation
- 2008-01-25 WO PCT/IB2008/000229 patent/WO2008093227A1/en active Application Filing
- 2008-01-25 NZ NZ578638A patent/NZ578638A/en not_active IP Right Cessation
- 2008-01-25 CA CA2676670A patent/CA2676670C/en not_active Expired - Fee Related
- 2008-01-25 DK DK08702351.1T patent/DK2114970T3/da active
- 2008-01-25 GE GEAP200811399A patent/GEP20125404B/en unknown
- 2008-01-25 BR BRPI0808634-6A patent/BRPI0808634A2/pt not_active IP Right Cessation
- 2008-01-25 EP EP08702351A patent/EP2114970B1/en active Active
- 2008-01-28 RS RS20110008A patent/RS51646B/en unknown
- 2008-01-28 MY MYPI20093135A patent/MY148780A/en unknown
- 2008-01-28 ES ES08702358T patent/ES2353822T3/es active Active
- 2008-01-28 KR KR1020097018294A patent/KR101114682B1/ko not_active IP Right Cessation
- 2008-01-28 GE GEAP200811398A patent/GEP20125426B/en unknown
- 2008-01-28 UA UAA200907730A patent/UA95332C2/uk unknown
- 2008-01-28 PT PT08702358T patent/PT2114888E/pt unknown
- 2008-01-28 CN CN2008800056527A patent/CN101616896B/zh not_active Expired - Fee Related
- 2008-01-31 PE PE2008000231A patent/PE20081736A1/es not_active Application Discontinuation
- 2008-01-31 US US12/023,323 patent/US7547714B2/en not_active Expired - Fee Related
- 2008-01-31 US US12/023,362 patent/US7598231B2/en not_active Expired - Fee Related
- 2008-02-01 TW TW097104074A patent/TWI373466B/zh not_active IP Right Cessation
- 2008-02-01 TW TW097104089A patent/TWI347842B/zh active
- 2008-02-01 AR ARP080100425A patent/AR065135A1/es active IP Right Grant
- 2008-02-01 PE PE2008000234A patent/PE20090113A1/es not_active Application Discontinuation
- 2008-02-01 AR ARP080100424A patent/AR065134A1/es active IP Right Grant
- 2008-02-01 HN HN2008000179A patent/HN2008000179A/es unknown
- 2008-02-01 HN HN2008000178A patent/HN2008000178A/es unknown
- 2008-02-01 CL CL200800330A patent/CL2008000330A1/es unknown
- 2008-02-01 CL CL200800329A patent/CL2008000329A1/es unknown
2009
- 2009-05-08 US US12/437,704 patent/US8158660B2/en not_active Expired - Fee Related
- 2009-07-20 IL IL199972A patent/IL199972A/en active IP Right Grant
- 2009-07-21 US US12/506,825 patent/US7786097B2/en not_active Expired - Fee Related
- 2009-07-23 CR CR10948A patent/CR10948A/es not_active IP Right Cessation
- 2009-07-23 CR CR10949A patent/CR10949A/es not_active IP Right Cessation
- 2009-07-24 CU CU20090133A patent/CU23824A3/es active IP Right Grant
- 2009-07-24 CU CU2009000132A patent/CU23848B1/es active IP Right Grant
- 2009-07-29 DO DO2009000190A patent/DOP2009000190A/es unknown
- 2009-07-29 NI NI200900149A patent/NI200900149A/es unknown
- 2009-07-29 NI NI200900148A patent/NI200900148A/es unknown
- 2009-07-30 GT GT200900209A patent/GT200900209A/es unknown
- 2009-07-30 GT GT200900210A patent/GT200900210A/es unknown
- 2009-07-30 SV SV2009003346A patent/SV2009003346A/es not_active Application Discontinuation
- 2009-07-31 EC EC2009009552A patent/ECSP099552A/es unknown
- 2009-07-31 SV SV2009003349A patent/SV2009003349A/es active IP Right Grant
- 2009-07-31 MA MA32128A patent/MA31158B1/fr unknown
- 2009-07-31 TN TNP2009000324A patent/TN2009000324A1/fr unknown
- 2009-07-31 EC EC2009009553A patent/ECSP099553A/es unknown
- 2009-07-31 MA MA32127A patent/MA31117B1/fr unknown
- 2009-07-31 CO CO09079796A patent/CO6190603A2/es active IP Right Grant
- 2009-07-31 CO CO09079789A patent/CO6220937A2/es active IP Right Grant
- 2009-09-01 ZA ZA200906060A patent/ZA200906060B/xx unknown
- 2009-09-01 ZA ZA200906064A patent/ZA200906064B/xx unknown
2010
- 2010-02-12 HK HK10101635.7A patent/HK1135108A1/xx not_active IP Right Cessation
- 2010-12-02 CY CY20101101109T patent/CY1110962T1/el unknown
2011
- 2011-08-17 CY CY20111100784T patent/CY1111758T1/el unknown
- 2011-10-03 HR HR20110702T patent/HRP20110702T1/hr unknown
- 2011-12-21 US US13/333,104 patent/US8445520B2/en not_active Expired - Fee Related
2013
- 2013-04-16 US US13/863,534 patent/US20140142316A1/en not_active Abandoned
2014
- 2014-07-01 US US14/320,674 patent/US8901310B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW200846325A (en)	2008-12-01
MY146087A (en)	2012-06-29
GT200900210A (es)	2010-04-05
CR10949A (es)	2009-08-07
GEP20125426B (en)	2012-03-26
MX2009008284A (es)	2009-08-12
PT2114970E (pt)	2011-09-22
EP2114970B1 (en)	2011-08-03
ZA200906060B (en)	2010-05-26
HN2008000179A (es)	2010-06-09
US20080312294A1 (en)	2008-12-18
JP4599462B2 (ja)	2010-12-15
WO2008093227A1 (en)	2008-08-07
MA31117B1 (fr)	2010-01-04
CU20090133A7 (es)	2011-10-31
UA95332C2 (uk)	2011-07-25
RS51646B (en)	2011-10-31
HK1135108A1 (en)	2010-05-28
CN101616896A (zh)	2009-12-30
IL199972A (en)	2013-09-30
BRPI0808634A2 (pt)	2014-08-05
AR065134A1 (es)	2009-05-20
NI200900149A (es)	2010-02-15
CL2008000329A1 (es)	2008-08-08
CR10948A (es)	2009-08-07
RS51970B (en)	2012-02-29
CL2008000330A1 (es)	2008-08-08
UA94639C2 (ru)	2011-05-25
TW200838514A (en)	2008-10-01
US20100286214A1 (en)	2010-11-11
CU23848B1 (es)	2012-10-15
SV2009003349A (es)	2010-04-13
NI200900148A (es)	2010-02-15
KR20090107080A (ko)	2009-10-12
US7786097B2 (en)	2010-08-31
AP2455A (en)	2012-08-31
ECSP099552A (es)	2009-08-28
US8445520B2 (en)	2013-05-21
KR101107949B1 (ko)	2012-02-08
CY1111758T1 (el)	2015-10-07
SI2114970T1 (sl)	2011-11-30
CA2676670A1 (en)	2008-08-07
US20140316139A1 (en)	2014-10-23
MY148780A (en)	2013-05-31
PE20081736A1 (es)	2008-11-28
US8158660B2 (en)	2012-04-17
US20120095062A1 (en)	2012-04-19
ATE518872T1 (de)	2011-08-15
SV2009003346A (es)	2010-04-13
CN101616896B (zh)	2012-07-04
DK2114970T3 (da)	2011-09-19
GT200900209A (es)	2010-07-22
ES2368286T3 (es)	2011-11-16
HN2008000178A (es)	2011-02-25
AP2009004942A0 (en)	2009-08-31
TN2009000324A1 (fr)	2010-12-31
US20080188443A1 (en)	2008-08-07
KR20090108115A (ko)	2009-10-14
PT2114888E (pt)	2011-01-04
ECSP099553A (es)	2009-08-28
KR101114682B1 (ko)	2012-03-14
TWI373466B (en)	2012-10-01
DOP2009000190A (es)	2009-08-31
US20140142316A1 (en)	2014-05-22
EP2114970A1 (en)	2009-11-11
CU20090132A7 (es)	2011-10-14
US7547714B2 (en)	2009-06-16
AU2008211613A1 (en)	2008-08-07
CN101616925A (zh)	2009-12-30
HRP20110702T1 (hr)	2011-10-31
GEP20125404B (en)	2012-02-27
US8901310B2 (en)	2014-12-02
CO6190603A2 (es)	2010-08-19
EA200970666A1 (ru)	2010-02-26
AU2008211613B2 (en)	2013-05-23
CY1110962T1 (el)	2015-06-11
CO6220937A2 (es)	2010-11-19
US7598231B2 (en)	2009-10-06
AR065135A1 (es)	2009-05-20
CN101616925B (zh)	2012-05-23
ZA200906064B (en)	2010-05-26
TWI347842B (en)	2011-09-01
US20090281148A1 (en)	2009-11-12
EA016494B1 (ru)	2012-05-30
IL199972A0 (en)	2010-04-15
PL2114970T3 (pl)	2011-11-30
CU23824A3 (es)	2011-10-31
PE20090113A1 (es)	2009-02-13
NZ578638A (en)	2010-12-24
CA2676670C (en)	2012-03-13
ES2353822T3 (es)	2011-03-07
MA31158B1 (fr)	2010-02-01
US20120088802A9 (en)	2012-04-12
JP2010517990A (ja)	2010-05-27

Publication	Publication Date	Title
MY153057A (en)	2014-12-31	Tryclic compounds,compositions and methods
MY171577A (en)	2019-10-21	2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EA201201648A1 (ru)	2013-06-28	Стимуляторы sgc
MA32257B1 (fr)	2011-04-01	Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
UA110943C2 (uk)	2016-03-10	N-ацилсульфонамідні промотори апоптозу
IN2014CN04907A (es)	2015-09-18
TW200608960A (en)	2006-03-16	3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TN2012000578A1 (en)	2014-04-01	Tetrahydro-pyrido-pyrimidine derivatives
TW200608966A (en)	2006-03-16	3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200734323A (en)	2007-09-16	3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2012012902A (es)	2012-12-17	Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
MX2013012652A (es)	2014-05-27	Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
GEP20156372B (en)	2015-09-25	Pyridazinone compounds and their use as daao inhibitors
MX2009008286A (es)	2009-08-12	Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
MX2011006006A (es)	2011-09-08	Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MY167898A (en)	2018-09-26	Co-crystals and salts of ccr3-inhibitors
EA201200570A1 (ru)	2012-11-30	Соединения и композиции в качестве модуляторов активности gpr119
MX2011009493A (es)	2011-10-11	Compuestos para el tratamiento de trastornos metabolicos.
MX2009003645A (es)	2009-04-22	Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MX337849B (es)	2016-03-09	Composiciones y metodos para inhibicion de la via jak.
NZ601383A (en)	2014-07-25	Methods and compositions for improved nerve conduction velocity
MA32945B1 (fr)	2012-01-02	Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
TW200740766A (en)	2007-11-01	Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
GB0609897D0 (en)	2006-06-28	Compounds
UA99198C2 (ru)	2012-07-25	Соединения фенантренона, композиция, содержащая их, и способ лечения